Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Promis Neurosciences (ARFXF : OTC)
 
 • Company Description   
ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.09 Daily Weekly Monthly
20 Day Moving Average: 162,201 shares
Shares Outstanding: 431.73 (millions)
Market Capitalization: $36.70 (millions)
Beta: 1.08
52 Week High: $0.23
52 Week Low: $0.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.14% -3.31%
12 Week -15.00% -6.56%
Year To Date -25.37% -15.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1920 Yonge Street Suite 200
-
Toronto,A6 M4S 3E2
CAN
ph: 416-847-6898
fax: -
None http://www.promisneurosciences.com
 
 • General Corporate Information   
Officers
Eugene Williams - Chief Executive Officer and Chairman
Gavin T. Malenfant - Chief Operating Officer
Daniel Geffken - Chief Financial Officer
Richard Gregory - Director
Patrick Kirwin - Director

Peer Information
Promis Neurosciences (CORR.)
Promis Neurosciences (RSPI)
Promis Neurosciences (CGXP)
Promis Neurosciences (BGEN)
Promis Neurosciences (GTBP)
Promis Neurosciences (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74346M109
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 431.73
Most Recent Split Date: (:1)
Beta: 1.08
Market Capitalization: $36.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.15
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 22.22%
ROE
03/31/22 - -268.06
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -36.36
12/31/21 - -27.60
09/30/21 - -20.99
Current Ratio
03/31/22 - -
12/31/21 - 19.07
09/30/21 - 13.29
Quick Ratio
03/31/22 - -
12/31/21 - 19.07
09/30/21 - 13.29
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -71,814.04
09/30/21 - -188,900.00
Book Value
03/31/22 - -
12/31/21 - 0.01
09/30/21 - 0.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.66
09/30/21 - 0.50
Debt-to-Capital
03/31/22 - -
12/31/21 - 39.80
09/30/21 - 33.42
 

Powered by Zacks Investment Research ©